Justin B. Klee
CIK: 0001898314
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Amylyx Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29K shares at avg. $32.13$933K - Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct1.4K shares at avg. $33.16$48K - Aug 18, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct60K shares- - Mar 5, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct248.9K shares- - Mar 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29.3K shares at avg. $14.47$424K - Feb 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct15.5K shares at avg. $14.69$228K - Jan 16, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct2.8K shares at avg. $7.57$22K - Jan 16, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct2K shares at avg. $13.89$28K - Jan 15, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct136.2K shares at avg. $13.58$1.8M - Jan 15, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct197.2K shares at avg. $7.57$1.5M - Jan 6, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.7K shares at avg. $11.09$86K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct200 shares at avg. $15.01$3K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct29.8K shares at avg. $14.37$428K - Mar 31, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct21.5K shares at avg. $3.46$74K - Mar 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct180.1K shares- - Mar 3, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct4.6K shares at avg. $3.15$14K - Feb 5, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct36.3K shares at avg. $1.57$57K - Feb 3, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct11.9K shares at avg. $3.47$41K - Jan 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.5K shares at avg. $4.04$30K - Nov 4, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct63.7K shares at avg. $1.57$100K - Sep 30, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct18.6K shares at avg. $3.20$59K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,025 | $32.13 | $932,553 | Direct |
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 1,439 | $33.16 | $47,710 | Direct |
| Aug 18, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 60,039 | - | $0 | Direct |
| Mar 5, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 248,865 | - | $0 | Direct |
| Mar 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,282 | $14.47 | $423,760 | Direct |
| Feb 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 15,500 | $14.69 | $227,618 | Direct |
| Jan 16, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 2,847 | $7.57 | $21,552 | Direct |
| Jan 16, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 1,995 | $13.89 | $27,701 | Direct |
| Jan 15, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 136,193 | $13.58 | $1,849,869 | Direct |
| Jan 15, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 197,153 | $7.57 | $1,492,448 | Direct |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,715 | $11.09 | $85,589 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 200 | $15.01 | $3,002 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 29,775 | $14.37 | $427,950 | Direct |
| Mar 31, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 21,490 | $3.46 | $74,454 | Direct |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 180,118 | - | - | Direct |
| Mar 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 4,595 | $3.15 | $14,483 | Direct |
| Feb 5, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 36,310 | $1.57 | $57,007 | Direct |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 11,855 | $3.47 | $41,104 | Direct |
| Jan 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,471 | $4.04 | $30,202 | Direct |
| Nov 4, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 63,690 | $1.57 | $99,993 | Direct |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 18,589 | $3.20 | $59,429 | Direct |
1-21 of 21 transactions
About Klee Justin B.
Klee Justin B. (SEC CIK 0001898314) files insider reports with the SEC as Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (AMLX).
Signal8 holds 16 ownership filings by Klee Justin B., all Form 4s, filed between Oct 2, 2024 and Sep 14, 2026. Those filings report 21 transactions, from Sep 30, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Klee Justin B.'s filings is in CAMBRIDGE, MA.
Recent filings by Klee Justin B.
- Sep 10, 2026: Open-market sales of AMLX shares (2 lines, Form 4, code S).
- Aug 18, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 5, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
- Feb 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
Other insiders filing for Amylyx Pharmaceuticals, Inc. (AMLX)
- MILNE GEORGE M JR, Director
- Bedrosian Camille L, Chief Medical Officer
- FRATES JAMES M, Chief Financial Officer
- Mazzariello Gina, Chief Legal Officer
- Cohen Joshua B, Co-Chief Executive Officer
- Firestone Karen, Director